DrMcPharma

DrMcPharma

By DrMcPharmaScienceLife Sciences
Download on the App Store

DrMcPharma episodes

  • Ep. 6. CRISPR: Bacterial Oddity to Gene Editing Revolution

    The History of CRISPR: From Discovery to Therapeutic Development


    Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) have emerged as a revolutionary gene-editing technology, fundamentally altering the landscape of biological research and opening unprecedented avenues for therapeutic development. This technology, initially a curious observation within the genomes of bacteria, has undergone a remarkable journey to become a Nobel Prize-winning tool with the potential to address a vast spectrum of human diseases.


    The journey of CRISPR from an obscure observation in bacterial genomes to a revolutionary tool in medicine is a testament to the power of basic scientific curiosity and the potential for unexpected translational impact. Key milestones include the initial discovery of repeated sequences in E. coli, their subsequent identification in archaea, the elucidation of their role in bacterial immunity by Mojica, Horvath, and Barrangou, and the transformative repurposing of the CRISPR-Cas9 system for precise genome editing by Charpentier and Doudna, followed by its application in mammalian cells by Zhang and Church. The first regulatory approvals of CRISPR-based therapies for sickle cell disease and beta-thalassemia mark a significant achievement in therapeutic development, with a wide range of ongoing clinical trials exploring its potential for treating other genetic disorders, cancer, infectious diseases, and beyond. Challenges related to delivery, immunogenicity, off-target editing, and long-term safety remain areas of active research. The development of advanced CRISPR technologies like base editing and prime editing, along with the discovery of new Cas enzymes, holds immense promise for overcoming these limitations and expanding the therapeutic reach of gene editing. As CRISPR continues to evolve, careful consideration of the ethical and societal implications, alongside robust regulatory frameworks, will be essential to ensure its responsible and equitable application in transforming the future of medicine.

    22 min
  • Ep. 3. Science Shockwave: Decoding the Breakthroughs, Funding Frenzy, and Policy Changes Reshaping America

    The Current State of Science in the United States Since January 1st, 2025


    Executive Summary

    Since the beginning of 2025, the scientific landscape in the United States has been marked by significant advancements across various disciplines, alongside notable shifts in funding and policy. Breakthroughs in medicine have seen progress in gene therapy for previously intractable conditions, the development of promising cancer vaccines and targeted therapies, and the increasing integration of artificial intelligence in diagnostics and drug discovery. Space exploration continues to yield discoveries with the identification of a substantial number of new moons around Saturn and the ongoing search for habitable exoplanets. In physics, quantum computing is advancing rapidly, and novel materials with sustainable properties are being developed. Biology continues to be a hotbed of innovation, with further understanding of CRISPR technology and its applications, as well as discoveries of new biological mechanisms and species. Technology continues its rapid evolution with the rise of more sophisticated artificial intelligence, advancements in brain-computer interfaces, and the ongoing development of renewable energy and energy storage solutions.

    However, this period has also been characterized by considerable changes in the funding landscape for scientific research. Proposed federal budget cuts to key agencies such as the National Science Foundation, NASA, and the National Institutes of Health have raised concerns within the scientific community. Simultaneously, policy shifts at these and other agencies, including changes related to diversity, equity, and inclusion initiatives and international collaborations, are reshaping the research environment. These developments present both challenges and opportunities for the US scientific enterprise, impacting its trajectory and global competitiveness. While private funding sources continue to play a vital role, the potential long-term consequences of reduced federal support are a significant point of discussion. The interplay of these factors—scientific progress, funding shifts, and policy changes—defines the current state of science in the United States.

    29 min
  • Ep. 2. Antibiotic Resistant: Racing Against Resistance and the Urgent Hunt for New Antibiotics

    Recently Approved Antibiotics (2023-2024)

    | Drug Name | Approval Date (YYYY-MM) | Mechanism of Action | Indication(s) | Snippet ID(s) |

    |---|---|---|---|---|

    | Pivya (pivmecillinam) | 2024-04 | Inhibits bacterial cell wall synthesis | Uncomplicated urinary tract infections (UTI) in adult women | |

    | Orlynvah (sulopenem etzadroxil and probenecid) | 2024-10 | Oral penem antibiotic | Uncomplicated UTI caused by E. coli, Klebsiella pneumoniae, or P. mirabilis in adult women with limited or no alternative oral options | |

    | Exblifep (cefepime and enmetazobactam) | 2024-02 | Combines a cephalosporin with a beta-lactamase inhibitor | Complicated UTIs, including pyelonephritis | |

    | Xacduro (sulbactam, durlobactam) | 2023-05 | Beta-lactamase inhibitor combination | Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex |


    Examples of Novel Antibiotic Candidates in Development (2023-2024)

    | Candidate Drug Name | Target Pathogen(s) | Mechanism of Action | Stage of Development | Snippet ID(s) |

    |---|---|---|---|---|

    | Zosurabalpin (RG6006) | Invasive Gram-negative bacteria | Disrupts LPS transport mechanism | Clinical Trials | |

    | Cresomycin | Gram-positive and Gram-negative bacteria, MDR strains | Inhibits bacterial protein synthesis by binding to the ribosome | Preclinical | |

    | Darobactin D22 | Priority Gram-negative pathogens (E. coli, P. aeruginosa, A. baumannii) | Binds to an essential protein in bacterial cells | Animal Trials | |

    | Macrolones | Broad range of bacteria | Dual action: inhibits protein production and corrupts DNA structure | Preclinical | |

    | OXF-077 | MRSA | Inhibits the SOS response in bacteria, suppressing resistance evolution | Preclinical |



    Key Funding Initiatives and Organizations in Antibiotic R&D

    | Organization/Initiative Name | Focus Area | Key Activities/Goals | Snippet ID(s) |

    |---|---|---|---|

    |CARB-X | Preclinical research | Funds preclinical research and development of new antibiotics, diagnostics, and vaccines|

    |GARDP | Research, development, and access | Develops and makes accessible antibiotic treatments for people who need them, focusing on public health needs and LMICs|

    |BARDA | Medical countermeasures (including antibacterials and antifungals) | Supports the development of medical countermeasures for CBRN threats, pandemic influenza, and emerging infectious diseases|

    |AMR Action Fund | Clinical-stage antibiotic development | Invests in companies to bring 2-4 new antibiotics to patients by 2030, focusing on WHO-prioritized pathogens|

    |NIAID (ARLG) | Antibiotic resistance research, clinical trials, diagnostics, stewardship | Supports multisite studies on antibiotic resistance, informs clinical practice, develops diagnostics, and trains researchers|

    |Global AMR R&D Hub | Coordination and funding of AMR R&D | Aims to strengthen the global response to AMR by identifying gaps, encouraging collaboration, and monitoring progress in research and development|


    18 min

About DrMcPharma

From the publisher's feed

Clinician-Scientist 🧫🧬🔬⚗️🧪👩🏼‍🔬👨🏻‍🔬